François JettéFrançois Jetté, CA

Chief Financial Officer

Mr. Jetté has been Chief Financial Officer of Warnex since April 2008. From November 2005 to March 2008, he was Warnex's Corporate Controller. From 1999 until joining Warnex, Mr. Jetté was Controller for Pretium Canada Company. From 1997 to 1999, he was Controller for Naya Inc.


Dr. Michael ManciniDr. Michael Mancini

President, Warnex Bioanalytical Services

Dr. Mancini has been President of Warnex Bioanalytical Services since 2002. Dr. Mancini was also President of Warnex Analytical Services Inc. from June 2000 to March 2007. From 1996 until joining Warnex, he was Director of Business Development and Scientific Liaison with MDS Pharma Services Inc. and prior to that, he was Head of the Bioanalytical department of LAB-BioResearch. Dr. Mancini holds a Ph.D. in Chemistry from McGill University, where his research focused on the synthesis of a new class of anticancer drugs. He completed two years of postdoctoral work developing synthetic strategies for novel anti-viral agents modeled after AZT before joining the National Research Council's Biotechnology Research Institute (BRI) as a Research Associate in the Protein Engineering Department. During his tenure at BRI, he developed his interest in mass spectrometry, which led to his career in contract research.


The Executive Committee of the Board of Directors of Warnex oversees the senior officers of Warnex. The Executive Committee is chaired by Mr. Michael Singer, Chief Financial Officer of Thallion Pharmaceuticals Inc. Other members of the Executive Committee include Messrs. Richard Laferriere, Michel Lassonde and Marc Lebel.

Stock Quote

TSX: WNX   High: 0.015
Open: 0.015 Low: 0.015
Canadian $    Quotes are delayed.


2010 Annual Report (PDF: 643 Kb)
Corporate presentation (PDF: 3.43 Mb)

Latest News

February 2, 2012
Warnex Extends Maturity Date of Its Outstanding Debenture
January 12, 2012
Warnex Comments on its Listing Status